The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 74 (high attention) · dilution pressure high · listing risk elevated · governance risk low · runway 0.8 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (shelf effective, shelf filed). Base case is a discounted raise; the question is when, not if.
On August 14, 2026, HCW Biologics filed an 8-K (Item 4.02) announcing that its Q1 2026 financials cannot be relied upon due to a material EPS misstatement. The company failed to properly apply the two-class method, overstating basic/diluted EPS by $0.80 per share (post-split) by allocating 100% of undistributed earnings to common stock instead of ~63% to common and ~37% to participating securities. Management concluded a material weakness exists in technical accounting review controls over complex warrant instruments. The same day, a press-release exhibit disclosed the company is before a Nasdaq hearings panel. Meanwhile, on July 29, the company completed a $1.6M private placement selling 218,682 shares and 400,000 pre-funded warrants (plus rights to common warrants subject to stockholder approval). Insiders—CEO Wong, Chairman Garrett, and SVP Flowers—participated. The Q2 10-Q filed August 14 shows $741,324 cash against $18.6M current liabilities as of June 30, indicating ~0.8 months of runway.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 80 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 8, 2026 | ▼ Reverse split | “reverse split” language in PRE 14A (PRE 14A) filed 2026-09-08 filing | 29 |
| Aug 31, 2026 | ▼ Shelf effective | EFFECT notice 2026-08-31 filing | 21 |
| Aug 28, 2026 | ▼ Shelf filed | S-1/A filed 2026-08-28 filing | 30 |
| Aug 20, 2026 | ▼ Shelf filed | S-1 filed 2026-08-20 filing | 30 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.8 months runway: liquidity $741,324 as of 2026-06-30, burn $11,236,655/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 44 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $6,200,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 25 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $741,324 vs current liabilities $18,648,173 filing | 22 |
AUID authID Inc. · SOBR SOBR Safe, Inc. · SDST Stardust Power Inc. · ADIL ADIAL PHARMACEUTICALS, INC. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · screener →